Argireline vs Botulinum toxin type A
Written by Aaron CuhaReviewed Sep 2026
The short answer
The peptide sold as Botox in a cream, and the injected product it is named after. They are not the same kind of thing, they do not go into the same tissue, and only one of them has a boxed warning.
- Argireline people
- 155
- Argireline nulls
- 1
- Botulinum toxin type A people
- 1,681
- Botulinum toxin type A nulls
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
4 completed trials, 155 people given it
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved. Botox was first approved on 9 December 1991 under BLA 103000. Other type A products were approved separately, including abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA and daxibotulinumtoxinA. Approved uses include chronic migraine, overactive bladder, stiff tight muscles (spasticity), neck muscle spasms (cervical dystonia), heavy underarm sweating, eyelid spasms and crossed eyes. There are separate cosmetic approvals for facial lines. All type A products carry a boxed warning, the FDA's strongest kind, that the toxin's effect can spread beyond the injection site. Units differ from product to product and cannot be swapped between brands.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
ArgirelineAcetyl Hexapeptide-8 (Argireline)
A skin cream peptide sold as a 'Botox-like' wrinkle softener for lines from facial expressions.
Column B
Botulinum toxin type ABotulinum neurotoxin type A (Botox, Dysport, Xeomin, Jeuveau, Daxxify)
A large bacterial protein that works as an enzyme, not a peptide. It was first approved in 1991 and carries the FDA's strongest warning, about the toxin spreading beyond where it was injected. Its medical uses far outnumber its cosmetic ones. In pooled migraine studies of 1384 people, headache days fell 8.4 a month on the toxin and 6.6 on dummy shots. For wrinkles, results are graded on frown-line scales and last roughly 3 to 6 months.
The mistake this page exists to correct
Argireline is marketed as a cream alternative to botulinum toxin, because both get in the way of the same nerve to muscle signal. Botulinum toxin type A is a large 150 kDa bacterial enzyme injected into muscle. It was first approved in 1991 and carries a boxed warning about the toxin spreading beyond the shot site. Its medical uses are bigger than its cosmetic ones. Argireline is a six building block peptide put on the skin surface, and the skin is the barrier the comparison ignores. For the shot, cosmetic results are judged by eye on wrinkle scales at the deepest frown, and last roughly 3 to 6 months. The evidence for the cream peptide is smaller, shorter and softer.
Side by side, on the facts we can check
| What we compare | Argireline | Botulinum toxin type A |
|---|---|---|
| Category | Cosmetic | Cosmetic |
| FDA status | Cosmetic ingredient; not an approved drug | FDA-approved. Botox was first approved on 9 December 1991 under BLA 103000. Other type A products were approved separately, including abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA and daxibotulinumtoxinA. Approved uses include chronic migraine, overactive bladder, stiff tight muscles (spasticity), neck muscle spasms (cervical dystonia), heavy underarm sweating, eyelid spasms and crossed eyes. There are separate cosmetic approvals for facial lines. All type A products carry a boxed warning, the FDA's strongest kind, that the toxin's effect can spread beyond the injection site. Units differ from product to product and cannot be swapped between brands. |
| Half-life | Topical (surface) | Not a meaningful plasma measure. The drug acts locally and is not detectable systemically at therapeutic doses; the duration of effect reflects how long it takes nerve terminals to regenerate, which is typically several months. |
| Molecular weight | 888.9 Da | About 150 kDa. A bacterial protein and an enzyme, not a peptide by any useful definition. |
| How it works | It copies part of a protein called SNAP-25. That slightly blocks the nerve signal that makes facial muscles squeeze, softening expression lines. | One half of the toxin grabs onto nerve endings that control muscles and glands, and the toxin gets pulled inside. The other half is an enzyme. It cuts a protein called SNAP-25. Nerve endings need SNAP-25 to release their chemical messenger. Without it, the message never gets out, and the muscle or gland goes quiet. Because it is an enzyme, a tiny number of toxin molecules can cut a huge number of SNAP-25 targets. That is why it is so strong. Recovery takes months. It depends on the nerve growing new endings and making new SNAP-25, not on the body clearing the drug. |
| Studies in people | 7 | 3 |
| Evidence | Moderate: 4 completed trials, 155 people given it | Strong: 2 completed trials, 1,681 people given it |
| Legal status, US | Allowed as a cosmetic ingredient; not a drug | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Argireline and Botulinum toxin type A?
Argireline: A skin cream peptide sold as a 'Botox-like' wrinkle softener for lines from facial expressions. Botulinum toxin type A: A large bacterial protein that works as an enzyme, not a peptide. It was first approved in 1991 and carries the FDA's strongest warning, about the toxin spreading beyond where it was injected. Its medical uses far outnumber its cosmetic ones. In pooled migraine studies of 1384 people, headache days fell 8.4 a month on the toxin and 6.6 on dummy shots. For wrinkles, results are graded on frown-line scales and last roughly 3 to 6 months.
Which has stronger research evidence, Argireline or Botulinum toxin type A?
Each compound gets a band worked out from facts we counted, with the math shown. Argireline is Moderate (4 completed trials, 155 people given it). Botulinum toxin type A is Strong (2 completed trials, 1,681 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Argireline and Botulinum toxin type A FDA-approved?
Argireline: Cosmetic ingredient; not an approved drug. Botulinum toxin type A: FDA-approved. Botox was first approved on 9 December 1991 under BLA 103000. Other type A products were approved separately, including abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA and daxibotulinumtoxinA. Approved uses include chronic migraine, overactive bladder, stiff tight muscles (spasticity), neck muscle spasms (cervical dystonia), heavy underarm sweating, eyelid spasms and crossed eyes. There are separate cosmetic approvals for facial lines. All type A products carry a boxed warning, the FDA's strongest kind, that the toxin's effect can spread beyond the injection site. Units differ from product to product and cannot be swapped between brands..
Related posts
Blog articles that cover Argireline or Botulinum toxin type A, newest first.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.